^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IMA-901

    i
    Other names: IMA-901
    Associations

    News

    Trials
    Company:
    Immatics
    Drug class:
    Immunostimulant, Cytotoxic T lymphocyte stimulant
    Related drugs:
    Associations

    News

    Trials
    2years
    Phase I/II study of multipeptide cancer vaccine IMA901 after single-dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long-term follow up. (PubMed, Int J Urol)
    This study demonstrated the safety and tolerability of IMA901 vaccine in Japanese RCC patients, and also showed that vaccination elicited an immune response.
    P1/2 data • Journal
    |
    CSF2 (Colony stimulating factor 2)
    |
    cyclophosphamide • IMA-901